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Mass spectrometry (MS) in combination with liquid chromatography (LC), or LC/MS, is the preferred 
technique for lipidomic analyses. One of the most used applications of lipidomics is the search for 
molecular markers that can be used to signal specific activation states and that, ultimately, can be used in 
the early diagnosis of diseases. Our recent studies with monocytes/macrophages stimulated by 
inflammatory stimuli have revealed changes that result in the accumulation of unusual lipids. These 
changes are sometimes stimulus-specific and thus, could be regarded as specific markers of activation. 
Two examples are discussed below that resulted from the lipidomic analysis of arachidonate-containing 
phospholipids, and the analysis of the fatty acid composition of neutral lipids accumulating in cytoplasmic 
lipid droplets. 
Transcription of the talk presented on Thursday October 27, 2016 at the Faculdade de Medicina de Ribeirão 
Preto, Universidade de São Paulo, Brazil, (Slide 1 – Title). 
 
 
Long time ignored for being supposedly boring, lipids are gaining more and more acceptance as key molecules 
in physiology and pathophysiology. Even today, for many scientists and non-scientists, the word "lipid" takes 
them to inevitably think of these substances as simple sources of food energy or as structural components of 
membranes. This vision, in addition to limited, is erroneous, because lipids are a lot more than that; they are 
fundamental in physiology and pathophysiology because they regulate intercellular communication (Slide 2 - 
Lipids Are Key to Signaling). Today, it is firmly established that lipids connect the messages coming from 
external sources to the execution of specific responses by these cells. From a general point of view, we could 
classify the stimuli that use lipids to communicate messages in three groups, not mutually exclusive. In the first 
place, the stimuli that signal through changes in the intracellular calcium concentration. To this group belong 
most hormones and neurotransmitters. These stimuli activate a phospholipase C that is specific for inositol lipids  
that generates two messengers, one of  lipid nature, diacylglycerol (DAG) and the other water-soluble, inositol 
trisphosphate (IP3). Both messengers cooperate in a synergistic manner in the execution of cellular responses. 
Next, we have those stimuli that induce cell death, here to the left. These stimuli activate another enzyme of 
lipid metabolism, similar to the previous one, but this one hydrolyzes sphingomyelin to generate ceramide, that 
activates routes leading to cell death. Finally we have another group of stimuli that signal through the activation 
of phospholipase A2, an enzyme that is slightly different from the previous ones in that it produces two 
messengers of lipid origin, with the peculiarity that both can act inside and outside the cells. The first of these is 
the lysophospholipid, which can be secreted and act on neighbouring cells, amplifying in this way the response. 
On the other hand, we have a free fatty acid, of great interest if it is arachidonic acid;  the precursor of an 
enormous collection of compounds with potent biological activity with both physiological and 
pathophysiological regulatory effects: the eicosanoids, namely prostaglandins, leukotrienes etc, which are 
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involved in homeostatic maintenance of a large number of tissues and organs (Slide 3 – Eicosanoids in 
Physiology), and also participate in physiopathological processes, in particular in the inflammatory reactions, of 
which they are essential mediators (Slide 4 – Eicosanoids in Pathology). Inflammation is the response of an 
organism to an aggression of any kind. Inflammation is required to warn the organism that something bad is 
going on and a fix is needed. As I imagine that you know, all human disease consists of an inflammatory 
component, to a greater or lesser degree. (Slide 5 – Eicosanoids in Pathology). Indeed some of them diseases 
that kill more people in the world are of origin inflammatory (diabetes, cardiovascular disease) and that is 
initiated by inflammations poorly cured that, with the time is chronic and produce a huge damage in them 
tissues surrounding and in last instance lead to the death. 
Well, as summary of all of the above we could make the following statement on the current vision of the 
lipids, where we emphasize that they are in fact the more important biological molecules since they regulate our 
vital functions and imbalances in lipid metabolism causes a large number of diseases. Therefore, if we want to 
cure these diseases, must know what lipids are involved and what is what make (Slides 6 & 7 – Current View of 
Lipids). For this mission, we have a very powerful tool, lipidomics. So what is lipidomics? There are many 
definitions, but we stick to te one provided by people (at the time) of the ICBL because it emphasizes the 
integrative aspect of this discipline (Slide 8 – What Is Lipidomics?). So, lipidomics is not only chemometrics; 
we need to put the findings in the appropriate biological context. 
Our lab has been doing lipidomics for quite a long time now, always with a focus in signaling lipid in 
immunity innate and inflammation (Slide 9 – Lipidomics in Valladolid). In this sense it is important to note that 
a lipidome is made up of thousands of different molecules with very different chemical structure. This makes 
lipidomics inherently complex, because there is much structural variety. Therefore, attempting to unravel the 
full lipidome of a given cell system is complex and complicated, unless you have enormous resources, both 
money and trained personnel (Slide 10 – Lipid Categories). Those who cannot play that league, use the “Julius 
Caesar” strategy, i.e. “divide and conquer”. That means specioalize in a bit of the lipidome and work thoroughly 
on it. So we we have focused on arachidonic acid (AA), on thre directions: (i) the oxygenated derivatives, (ii) all 
fatty acid relatives of the omega-6 series and also omega-3 and omega-9, and (iii) the phospholipids into which 
arachidonic acid is esterified (Slide 11 – Lipidomics in Valladolid). This takes us to a key concept in AA 
regulation by phospholipase A2 as shown before, which is that AA is not free in the cells and is produced "on 
demand", i.e. under stimulation to produce the oxygenated metabolites that are necessary each time. (Slide 12 – 
Role of Phospholipase A2 in Arachidonic Acid Release). The rest of the time is "hidden" in the membrane 
phospholipids. In human cells AA is distributed almost exclusively in three kinds of phospholipids, PC red, 
green PE and PI in yellow (Slide 13 - Role of Phospholipase A2 in Arachidonic Acid Release). This situation is 
actually more complex from a molecular point of view, because cells contain multiple enzymes with 
phospholipase A2 activity, all of them being potentially capable of effecting the release of AA from 
phospholipids. The PLA2s that participate in these processes can classified is in three families, c, s, and i, of 
which the cPLA2 is the key enzyme, sPLA2 is accessory, and iPLA2 does not seem to be directly involved in 
releasing the AA but in keeping the AA pools withing phospholipid by acyl exchange (Slide 14 –Distinct Roles 
in Signal Transduction for Each of the Phospholipase A2...). And things can get even more complicated if we 
take into account that AA is an intermediary of a seemingly futile cycle of deacylation/reacylation. The key here 
is that AA does not return to the phospholipid molecule from which it initially came out (Slide 15 – Free 
Arachidonic Acid Levels Depend on a Deacylation/Reacylation Cycle), because there are reactions of 
transacilacion between phospholipids where AA is transferred and therefore generates a specific distribution 
profile for each condition (Slide 16 – Arachidonic Acid Trafficking Among Phospholipids). In a nutshell, the 
homeostasis of the AA could be summarized as a tug-of-war between the cPLA2 by pulling on one side and the 
enzymes of the reacylation and transacylation pathways on the other (Slide 17 –The Arachidonic Acid Tug-of-
War). Thus, it is important to know which within each class of phospholipid molecular species is the AA and 
which and how much of each ais used during stimulation since this information can be very useful to study the 
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cellular regulation but also in identifying markers of different states of activation (Slide 18 – Lipidomics as a 
Useful Approach). 
This is the experimental protocol utilized (Slide 19 – Lipidomic Profiling of Arachidonic Acid-
containing Phospholipids). In these studies we use human monocytes and stimulate them with a typical innate 
stimulus, yeast-derived zymosan. This will activate the cells and will result in the activation of phospholipase 
A2, which leads to the release of the AA, and the production of eicosanoids. This all results in the loss of AA in 
cellular phospholipids. Then we stop the reactions, extract the lipids and analyze AA-containing phospholipids, 
which is easy because they will give a signal of 303 m/z in fragmentation experiments. As a control we use a 
thing called pyrrophenone, which is an inhibitor of phospholipase A2. Before moving on to  show data, a small 
comment on the nomenclature of lipids (Slide 20 – Glycerophospholipids. Nomenclature). Do not forget to 
mention the ethers (Slide 21 – Glycerophospholipids. Nomenclature) and the plasmalogens (Slide 22 –
Glycerophospholipids. Nomenclature). With this information, here we have what I call the arachidonome of 
human monocytes (Slide 23 –Arachidonic Acid-containing Phospholipids of Human Monocytes). This is 
already a 'diagnostic' result, it is already a lipid fingerprint of monocytes, because it presents unique 
characteristics that make it immediately identifiable as belonging to monocytes. For example, the high AA 
content in PE plasmalogens, and high content of AA in a single PI species. What we will do is to analyze the 
behavior of each them during cell activation. We would expect for them to go down with time. The time-courses 
of different kinds of phospholipids, PC are displayed (Slide 24 – Time-dependent Changes of Major AA-
containing PC Species After Zymosan Stimulation), PI (Slide 25 – Time-dependent Changes of Major AA-
containing PI Species After Zymosan Stimulation), and PE (Slide 26 – Time-dependent Changes of Major AA-
containing PE Species After Zymosan Stimulation), emphasizing the appearance of species showing unusual 
behavior, i.e. increases. Studies with other stimuli indicate that one of them is specific of stimulus; these species 
could be regarded as markers of specific activation states, since they occur under certain conditions, but not for 
all (Slide 27 – What About Other Stimuli?). As a conclusion of these experiments is that, apart from their value 
as possible biomarkers, we could try to go a little further and try to study their function at the molecular level, 
what is the reason why cells make them (Slide 28 – Conclusions). A strategy to study this could be to isolate 
these lipids and introduce them in the cells to mimic a situation of activation. To get more on this, we will focus 
on PI(20:4/20:4) because it is an anionic phospholipid and as such, it can be transfectedm just like you would do 
with DNA or RNA (Slide 29 – Intracellular Delivery of Anionic Phospholipids). The protocol to study 
biological actions shown in the following figure (Slide 30 – Incorporation of PI(20:4/20:4) Into Cells). We 
focused on early responses such as the production of reactive oxygen metabolites. To the test the effect of  
PI(20:4/20:4) we studied whether the response was changed in cells loaded with this lipid (Slide 31 –  
PI(20:4/20:4) Regulates Superoxide Anion Production). We tried another response of innate immunity such as 
lysozyme secretion and observed a similar behavior (Slide 32 – PI(20:4/20:4) Regulates Lysozyme Release). All 
of this leads us to postulate that this lipid could regulate innate immune responses in macrophages (Slide 33 - 
1,2-Diarachidonyl-sn-glycero-3-phosphoinositol). 
Well, so far we have spoken of lipidomic analysis of phospholipids containing arachidonic acid; so, 
what happens with those who have no arachidonic? (Slide 34 – What about phospholipids without 
arachidonate?). To study this use a protocol identical to the shown previously, in fact is the same slide, but with 
an important variation. In this case we analyzed not only the effects of pyrrophenone, but also those of an 
inhibitor of iPLA2-VIA, FKGK18, to analyze the possible contribution of this enzyme (Slide 35 – Lipidomic 
Profiling of Phospholipids Without AA). This figure shows an analysis by LC/MS of some of the most abundant 
species of PC without arachidonic and the effect of the inhibitors pyrrophenone and FKGK18 (Slide 36 - Major 
PC Species Without AA in Zymosan-stimulated Macrophages). Some of these species decrease with the 
activation, which indicates that they are hydrolysed. Pyrrophenone does not do anything, which is not is strange 
since this is an inhibitor of an enzyme that hydrolyzes lipids with arachidonic acid. However, FKGK18 
completely prevents hydrolysis of some of these species. Examples where reversion is total include PC(32:0) 
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and PC(34:1), older species that could be identified in experiments of fragmentation as PC(16:0/16:0) and 
PC(16:0/18:1). Total reversal in other two minor species, PC(32:1) and PC(34:2), which were identified as 
PC(16:0/16:1) and PC(16:0/18:2) was also observed. Therefore, it is striking that four phospholipids identified 
as iPLA2β substrates during zymosan activation all contain palmitic acid (16:0) esterified at the sn-1 position. 
Actually when we measured lysolipid production in activated macrophages, palmitoyl-lysoPC was the major 
species produced and this production was strongly blocked by FKGK18, again suggesting that iPLA2β may be a 
major contributor to this accumulation (Slide 37 – Lysophospholipid Production in Zymosan-stimulated 
Macrophages). Note in contrast the other major lysolipid produced in the activated macrophages, stearoyl-
lysoPC, whose levels are affected little by FKGK18 but strongly by pyrrophenone, suggesting a link of this 
species to cPLA2α. So in the end, as a conclusion of these experiments, in activated cells, iPLA2β displays some 
sort of specificity for PC molecules containing palmitic at the sn-1 position (Slide 38 –  iPLA2 May Have 
Preference for sn-1 palmitoyl PC). 
When we examined the inositol lipids we found a few of them that showed an unexpected behavior, as 
they increased instead of going down. However the increase was partially prevented by FKGK18 but not by 
pyrrophenone, suggesting that iPLA2β may be involved (Slide 39 – Minor PI Species Without  AA in Zymosan-
stimulated Macrophages). These species have in common that all possess a 16:1 fatty acid residue. And it is 
interesting to note that two of them, the two that increase the most, were not found in resting cells, suggesting 
that if the cells make them, they must have some biological function. So the question is, where does 16:1-PI 
come from? (Slide 40 – Where Does 16:1-PI Come from?). We measured all the phospholipids that have 16:1 
and this is what we found (Slide 41 – 16:1-containing Phospholipids in Resting Macrophages). Most of the fatty 
acid is in PC, especially in one species, PC(16:0/16:1), while all other classes contained lesser amounts. Now 
we remind you that this PC species is one of those that I shown in the previous slide that was hydrolyzed by 
iPLA during activation to give rise to palmitoyl-lysoPC. So we measured the levels of the 16:1-containing 
phospholipids and found that PC(16:0/16:1) was the only that decreased and the ones that increased were the 
two preexisting PI molecules plus the 2 newly-formed (Slide 42 – 16:1-containing Phospholipids in Stimulated 
Macrophages). So, it is likely that much of the 16:1 fatty acid accumulating in PI comes from PC in a reaction 
that is sensitive to FKGK18 and thus probably mediated by iPLA2β (Slide 43 – Where Does 16:1-PI Come 
from? PC(16:0/16:1). One problem with this explanation is that the amount lost from PC is generally less than 
the amount gained by the PIs. Thus there is possibly a second source for 16:1 for PI. Because of this, we 
extended our analysis of distribution of 16:1 among lipid classes, also to neutral lipids, and we did this by 
GC/MS. We were surprised to find that, depending on the lipid class measured, there were two peaks of 16:1 
(phospholipids) or only one (neutral lipids) (Slide 44 – Two 16:1 Isomers in Macrophages). Comparison with 
commercial standards indicated that one was 16:1n-7 or palmitoleic acid proper and the other could either be 
16:1n-10 (sapienic acid) or 16:1n-9 (Slide 45 – Two 16:1 Isomers in Macrophages). We made the DMOX 
derivative and analyzed it by electron impact MS. Confirming it was actually 16:1n-9, a relatively unusual fatty 
acid (Slide 46 – The Second Isomer is 16:1n-9).  
What is the metabolic origin of 16:1n-9? (Slide 00 – Metabolic Origin of 16:1n-9). Since there are no ∆7 
desaturases in mammalian cells, a likely possibility is that it derives from oleic acid (18:1n-9). Incubation of the 
cells with oleic acid increased the levels of 16:1n-9 (Slide 00 – Enrichment with Oleic Acid Increases Cellular 
16:1n-9 Levels). This question was analyzed more directly by using deuterated oleic acid (Slide 00 – Fatty Acid 
Methyl Ester (FAME) Fragmentation Spectra). There are clear differences between the spectra of native and 
deuterated oleic acid, and incubation of the cells resulted in the appearance of a second deuterated fatty acid 
with the expected mass of 16:1n-9 and characteristic fragments consistent with it being 16:1n-9 (Slide 00 – 
Fatty Acid Methyl Ester (FAME) Fragmentation Spectra). Finally, if oleic acid is the actual precursor of 16:1n-9 
this has to coccur via β-oxidation; etomoxir, an inhibitor of this route, blunts 16:1n-9 accumulation (Slide 00 – 
Effect of Etomoxir on 16:1n-9 Accumulation). So, as a summary of these data it seems that strikingly, during 
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activation, immunoinflammatory stimuli activate both biosynthesis and discrete metabolism of fatty acids to 
generate diversity (Slide 00 – Lipid Inflammatory Signals Regulate Cellular Lipid Metabolism). 
As stressed before, there is a fundamental difference in the distribution of these two isomers among 
lipid classes, the n-9 isomer localizes in both phospholipid and neutral lipids, whereas n-7 only appears in 
phospholipid (Slide 47 – Distribution of 16:1 Isomers Between Lipid Classes). This distribution of n-9 is quite 
peculiar since no other fatty acid distributes similarly (Slide 48 – Distribution of 16:1 Isomers Between Lipid 
Classes). When we analyzed the distribution of n-9 in zymosan-treated cells, we found that it increases in all 
lipid classes but the highest increases are in neutral lipids (Slide 49 – Distribution of 16:1 Isomers Between 
Lipid Classes).   
The unique distribution of 16:1n-9 among cellular lipids and the finding that its levels are increased 
during cellular activation suggest a specific biological role for this unusual fatty acid. To study this question, we 
prepared cells enriched in this fatty acid by incubating them with 10 µM 16:1n-9 for 2 h in serum-free medium. 
This procedure results in the cells taking up the fatty acid and preferentially accumulating it in neutral lipids, in 
a similar manner as if they had been previously activated with a receptor-directed stimulus (Slide 50 – 
Assessing the Biological Effects of 16:1n-9).  Then, the cells were stimulated with LPS and the effects on the 
expression of a number of proinflammatory genes was investigated (Slide 51 – 16:1n-9 Possesses Anti-
inflammatory Properties in vitro). Cells enriched in 16:1n-9 showed significant decreases in the expression of all 
genes tested, and such decreases were generally comparable to those found in the 22:6n-3-treated cells. 16:1n-9 
was significantly more potent than 16:1n-7 for all genes tested; 16:1n-7 had significant effects only in two of 
them, Tnf and Nos2. These data show  that 16:1n-9 has a spectrum of biological activity that is clearly 
distinguishable from that of 16:1n-7. We also conducted experiments with mice (Slide 52 – 16:1n-9 Possesses 
Anti-inflammatory Properties in vivo). In these experiments, the fatty acid was administered i.p. to mice 1 h 
before i.p. injection of LPS for 6 h. Afterward, the animals were sacrificed, peritoneal cells were harvested, cell 
samples matched by protein content, and the expression levels of Il6 were studied. Both 16:1n-9 and 22:6n-3 
inhibited Il6 gene expression by the peritoneal cells isolated after the LPS challenge. Analysis of serum IL-6 
protein confirmed a strong decrease in the amount of circulating IL-6 protein in the 16:1n-9-treated mice. 
Unexpectedly, IL-6 protein levels in serum from 22:6n-3 treated cells were no different from those in serum 
from control untreated animals. 
I will finish my talk by emphasizinh once again the usefulness of a lipidomics approach to find markers 
of activation and new molecules with roles hitherto unknown in inflammation, such as PI(20:4/20:4) and 16:1n - 
9, keeping always in mind a sentence that I had introduced eary in my talk: "if we are going to solve..." (Slide 
53 – Lipid Markers of Activation). And in that regard, let me finish with a small lesson on history of medicine 
by remembering that the type of studies and information we get from lipidomics complies with something that a 
man prophesized more than 100 years ago, Johan Ludwig Thudichum (Slide 54 – The Need for Metabolomics), 
and what science thought about Thudichum shortly after his death (Slide 55 – Thudichum). Just a couple of 
minutes more to thank my collaborators and sources of support (Slide 56 – Acknowlegments). 
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